Abstract Introduction Interleukin-13 and interleukin-4 are type-II cytokines signalling through
the shared type II interleukin-4 receptor. As a result of their structural similarity, interleukin-13 …

Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma.
Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in …

Inflammation triggered by interleukin-4 (IL-4)/IL-13 is mediated by IL-4 and IL-13 receptors
that are present on multiple cell types, including epithelial cells, smooth muscle, fibroblasts …

Interleukin-13 (IL-13) is a pleiotropic cytokine produced by type-2 helper T-cells (Th2), mast
cells and basophils, and is thought to be involved in many of the features of asthma. IL-13 …

Abstract IL-4 and IL-13 are pleiotropic Th2 cytokines produced by a wide variety of different
cell types and responsible for a broad range of biology and functions. Physiologically, Th2 …

Some time ago, the Th2 cytokine, interleukin (IL)-13, was identified as a critical regulator of
the allergic response. Initial studies in animal models of disease provided compelling …

IL‐13 is a T‐helper type 2 cytokine. Animal models have implicated IL‐13 as a critical
cytokine in the development of asthma and chronic obstructive pulmonary disease (COPD) …

The future management of patients with allergic asthma is poised to change in the coming
one to two decades. This prediction is based on fundamental new insights into the …

Interleukin-13 (IL-13) as a pleiotropic cytokine acts through the IL-13Ra1/IL-4Ra complex to
induce activation responses which contribute to the inflammatory diseases. Genetic …

This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from
discovery of the molecule, the identification of its pathogenic role in animal models of …